COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$13.62 (+83.10%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.13B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.64
- Dividend yield
- –
- Free cash flow yield
- -6.03%
Fundamentals
- Net income
- -$377.18M
- EPS, diluted
- -$2.23
- Free cash flow
- -$309.24M
- Book value per share
- $3.11
- Diluted shares
- 171M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$389.09M
Net income
-$377.18M
EPS, diluted
-$2.23
Free cash flow
-$309.24M
Reported periodTrailing twelve months